Omnaris nasal spray is indicated for the treatment of seasonal allergic rhinitis (SAR) nasal symptoms and for perennial allergic rhinitis (PAR) nasal symptoms.
The corticosteroid is composed of a hypotonic pro-drug formulation which is highly tolerable and can provide fast relief, the company said.
Nycomed plans to introduce the product in other countries in the Middle Eastern region in 2012.
Omnaris is expected to address drug activation on the target cells, fast onset of action, increased absorption of ciclesonide and longer retention in the nasal mucosa compared to isotonic formulations, low systemic availability and low spray volume leading to a safety and tolerability profile compared to placebo.